Personalis Reports Strong Q1 Clinical Growth, Secures Lung Cancer Medicare Coverage, and Raises $21M via ATM at Premium

summarizeSummary

Personalis, Inc. announced Q1 2026 financial results, highlighting a 258% year-over-year increase in clinical test volume, new Medicare coverage for lung cancer, and the successful raise of $21.0 million through its At-The-Market program at a premium price.

check_boxKey Events

• Strong Clinical Volume Growth

  Clinical test volume surged 258% year-over-year and 26% sequentially to 7,815 tests in Q1 2026, reflecting strong market demand for the NeXT Personal test.

• Secures Medicare Coverage for Lung Cancer

  Received Medicare coverage approval for surveillance of cancer recurrence in Stage I to III non-small cell lung cancer (NSCLC) patients, marking the second major coverage decision in six months alongside breast cancer.

• Successful ATM Capital Raise

  Ended the quarter with approximately $233.2 million in cash, cash equivalents, and short-term investments, including $21.0 million in net proceeds from the At-The-Market (ATM) sales program, executed at a weighted-average price of $10.00 per share.

• Reaffirmed Full-Year 2026 Guidance

  Reaffirmed full-year guidance, projecting total revenue of $78.0 to $80.0 million, clinical test volume of 43,000 to 45,000 tests (171% growth), and clinical revenue of $10.0 to $11.0 million (roughly five-fold growth).

auto_awesomeAnalysis

Personalis, Inc. reported first-quarter results demonstrating significant progress in its 'Win-in-MRD' strategy. The substantial increase in clinical test volume and the critical Medicare coverage approval for lung cancer surveillance are key milestones for commercialization. While overall revenue declined due to a planned shift away from non-core services and net loss increased, these are expected as the company invests heavily in its strategic growth areas. The successful ATM capital raise at a price significantly above the current market price provides a strong financial runway and indicates institutional confidence, further bolstering the company's ability to execute its growth plans.